| Officer | Age | In this role | Joined | Pay | Source |
|---|---|---|---|---|---|
|
Grigorios Siokas
Also a director
Chief Executive Officer
|
60 | Not stated | Not stated | Not reported | |
|
Georgios Terzis
Chief Financial Officer
|
43 |
Since 2020
6 years
|
Not stated | Not reported | |
|
Nikolaos Bardakis
Chief Operating Officer
|
56 |
Since 2023
3 years
|
Not stated | Not reported | |
|
Demetrios G. Demetriades
Also a director
Secretary
Title from the Form 4 dated May 19, 2026
|
58 | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Non-interest bearing, no-term loans made by the CEO to the Company; outstanding principal balance of $0 at December 31, 2025 and $6,194 at December 31, 2024.
Repayment of loans to the CEO by a subsidiary through set-off against outstanding salary and bonus liabilities.
Non-interest bearing loan with no maturity date under a November 21, 2014 agreement, as amended November 4, 2016.
Prepaid balances to Doc Pharma at December 31, 2025.
Accounts payable balance to Doc Pharma at December 31, 2025, relating to trade payables of subsidiary Cosmofarm SA.
Trading receivables from Doc Pharma at December 31, 2025, relating to the Greek and UK subsidiaries; offset by a cumulative allowance.
Contract manufacturer outsourcing agreement dated October 10, 2020; inventory purchased under it during 2025.
Research and development agreement dated May 17, 2021; additional Sky Premium Life licenses acquired in 2024.
Royalty-bearing patent license agreement signed December 31, 2024; royalties incurred in the 12-month period.
Purchase of five branded pharmaceuticals from Zakalia Ltd., parent company of Doc Pharma, settled by reducing prepaid balances held with Doc Pharma.
Purchase of 19 generic licenses from Doc Pharma, settled by reducing prepaid balances held with Doc Pharma.
Conversion of prepaid balance into a 10-year loan to Doc Pharma bearing 5.5% fixed interest, maturing December 1, 2032.
Interest income recognized by the Company on the loan to Doc Pharma during 2025; no principal or interest received.
Advance payments to Kozaris for repurchase of his shares, recorded in prepaid expenses as a related party balance.
Issuance of 120,000 shares of common stock to Basotho Investment Limited for services rendered on November 21, 2023; fair value shown for 2024.
Net sales by Cosmofarm SA to Pharmacy & More, a pharmacy owned by Maria Kozari, under a more flexible credit policy.
Accrued but unpaid salaries and bonuses payable to the CEO at December 31, 2025.
Accrued but unpaid salaries and bonuses payable to the CFO at December 31, 2025.
Accrued but unpaid salaries and bonuses payable to the COO at December 31, 2025.
Loading...
